Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Psychiatry 17 (10), 10171025
Literature and video were very helpful
Research shows that its angiogenic and anti-inflammatory benefits may extend beyond the digestive system even in small doses
BPC-157's documented ability to modulate the nitric oxide pathway and reduce inflammatory cytokine expression in animal models suggests a potential role in the anti-inflammatory toolkit available to longevity-focused medicine, though this remains an extrapolation requiring human validation
Theoretical synergy: three pathways working together Triple-pathway hypothesis: Why it might work: Non-overlapping receptor pathways Complementary not redundant Multiple appetite suppression mechanisms Enhanced metabolic effects Potential for greater weight loss than either alone Comparison to proven combinations: CagriSema (semaglutide + cagrilintide): 15-25% proven Tirzepatide alone: 15-22% proven Theoretical tirzepatide + cagrilintide: 20-30% unproven The critical problem: no clinical data What we DON'T know: Is the combination safe
Hypothesis: Thanks to a stronger weight loss, CagriSema should lead to a superior reduction of MACE compared to Semaglutide in SELECT (where Semaglutide reduced MACE by 20 %)
US$ 29.91
US$ 22.28
US$ 22.27
